Sign in
CompletedEarly phase 1

Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People

Key facts

Who runs it
Medical University of South Carolina
Where
Charleston, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
15 people enrolled
Started
6 Aug 2024
Ended
13 Jan 2026
Type of study
Interventional
Treatments tested
  • Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder
Record updated
27 March 2026

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Currently pregnant and less than 33 weeks gestational age,
  • History of OUD within past 3 years,
  • Confirmed prescription for sublingual buprenorphine products (i.e., Suboxone, Subutex, Zubsolv) for the purpose of treating OUD,
  • Living in the United States,
  • Between 18-45 years of age

Who cannot take part

  • High-risk pregnancies including the following conditions: hyperemesis defined as hospitalization for intractable nausea and vomiting, hypertensive disorders of pregnancy (e.g., gestational hypertension, preeclampsia), placenta previa, or vaginal bleeding in current pregnancy after the first trimester
  • Experiencing cognitive or emotional impairment that precludes providing informed consent
  • Carrying multiples (i.e., twins, triplets, etc.)
  • Current psychotic symptoms and/or active suicidal intent
  • Incarcerated/pending incarceration or institutionalized during the study period

Where in United States

  • Medical University of South CarolinaCharleston, United States

About the trial

What the trial wants to find out

This study involves testing how useful a technology-enhanced intervention is for pregnant people prescribed buprenorphine for the management of opioid use disorder. The intervention being studied is a brief therapy protocol and a mobile application. Participation involves four 60-minute therapy appointments during pregnancy, and four 30-minute therapy appointments at the end of pregnancy through 3 months postpartum. The mobile application will be accessible for at least the duration of the study. Participants will also be asked to complete questionnaires at enrollment and again at 1-month postpartum and 3-months postpartum, will send monthly photos of their prescription bottle/box, and will be contacted randomly throughout the study to perform a medication count. The total duration of the study is between 5-9 months depending on when you enroll (early second trimester-mid third trimester). Compensation is provided.

The group in the trial

  • Empowering Pregnant Women and People Receiving Medications for Opioid Use DisorderTreatment being tested

    EMPWR is a two-pronged intervention model comprised of 1) a provider-driven, telemedicine-based behavioral intervention to mitigate anxiety sensitivity and sleep deficiency and enhance peripartum buprenorphine retention, and 2) an adjunctive mobile application to promote patients' buprenorphine adherence and use of therapy skills learned through the behavioral intervention. The EMPWR therapy protocol is comprised of five 30-60-minute sessions delivered weekly or biweekly by a therapist during the second and/or third trimester of pregnancy, and three 30-minute booster sessions delivered months 1-3 postpartum.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
EMPWR Pilot Trial: Treatment Retention in Medication for Opioid Use Disorder Among Pregnant and Postpartum Women
Record updated
27 March 2026